A tuberculosis cure is accelerated by immunotherapy targeting

In this episode, Styliani Karanika describes how their findings underscore the potential of a strategy to advance therapeutic TB vaccine development targeting M. tuberculosis persisters while providing a framework to define correlates of vaccine-mediated protection.

Genome/exome sequencing underestimates CHIP–disease associations

In this episode, Dr. Alexander G. Bick discusses how epidemiology studies underestimate how strongly clonal hematopoiesis is linked to disease because shallow whole-genome sequencing produces more false negatives compared with deep targeted sequencing.

Predicting chronic graft-versus-host disease and mortality risk with BIOPREVENT

In this episode, Sophie Paczesny explains that BIOPREVENT accurately predicts individual risk of future cGVHD and NRM using biomarkers at 3 months post-HCT. A publicly available R Shiny web application supports its clinical use. Further studies are needed to explore its role in guiding preemptive therapy.

Protective, subtype antibody family targets the active site of influenza A virus neuraminidase

In this video, Dr. Seth J. Zost presents an antibody lineage from a single donor that binds the active site of influenza neuraminidase, cross-reacts with antigenically diverse viruses, and protects mice from infection.

Capillary loss and fibrosis in experimental kidney disease is prevented with TIE2 activation

In this episode, Marie Jeansson explains how the paper's findings suggest that TIE2 activation via angiopoietin-2 (ANGPT2)-binding and TIE2-activating antibody warrants investigation as a therapy in human CKD, where there is a substantial unmet medical need.